Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! 2nd Global Bioequivalence Harmonisation Initiative – a great success Quality Management Systems in Early Phase Trials Trial in drug-induced xerostomia published Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
HPA axis CDM Healthy subjects FDA Safety Postmenopausal women Ocular tolerability Central surveillance system DUS Phase III HRT Highly variable drugs Investigators brochure Inspection Patients Bioavailability Immunogenicity Statistical programming Life cycle management Source Data Verification Paediatricians In vitro in vivo correlation Allergy IEC Standardisation Good Clinical Practice Pharmacology EMA Patient recruitment Clinical Monitoring Project Management Hormone replacement therapy Children MDI Authorities GCP Network GCP training Clinical study Referral system Biosimilars Feasibility Transdermal therapeutic system Data management Contraception ANVISA Auditing Sequential designs IB Clinical trials Phase IV Efficacy Clinical pharmacology unit HTA Product development Post authorisation Monitoring SDV Recruitment rates Biopharmaceutics Audit Expert Subcontractor qualification Spacious archive Drug Drug Interaction US FDA NIS WinNonlin Protocol development Phase II Oncologic network CRO Dry powder inhaler Bioequivalence Oncological patients Xerostomia Data Validation Plan Pulse oximetry plethysmography Clinical development program Sore throat Informed Consent Procedure Common cold Hypothalamic Quality Macular Creativity Metered dose inhaler Experience Centralised procedure Rhine Main area CRF OTC CDASH Training CDISC Glaucoma Early phase Cardiovascular surveillance Pilot study Pharmacodynamic studies CRA DDI Absorption Uveitis Edema Scientific expertise TTS Patch Quality Management System MCID PASS Charcoal GLP Quality Assurance Ophthalmology Non interventional CDSIC PAES Competence SAS Ovulation inhibition Database Phase IIb trials Patch adhesion Drug Food Interaction AGAH DFI Axis Local tolerability Pharmacokintetics Eye disease Ophthalmological trials Ophthalmologist Pharmacokinetics Sample size estimation Standard operating procedure FIM Pituitary Slit lamp microscopy Consultancy US CFR 21 Part 11 Phase I Elpro SocraTec C&S Dose linearity Dermal irritation Legal Information Endpoint Asthma Phase I Unit Female adolescents Protocol Scientific advice Cough SOP based DPI COPD Gynaecological trials IMPD Pragmatism ADAM ICF Degeneration Dry eye First in human Lung Absorption windows Data Management Plan Oncology Legal representative Thuringia Intensive assessment station IVIVC Biopharmaceutical Anaesthesiologist Sensitisation trials Design development Phase IIa trials Statistical services Biometrics Statistical Analysis Plan Copyright Steady state MMM Adrenocortical Inhalatives  
 
Menu

All fine on front page